Prime Medicine, Inc.
NASDAQ:PRMEBiotechnology
-$0.04 today
- Market cap
- $694.94M
- Beta
- 2.31
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$1.12
Volume 4.62M
Average 2.47M
PRME EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Prime Medicine, Inc.NASDAQ: PRME
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$47.27M, compared with -$50.19M a year earlier. Trailing-twelve-month EBITDA was -$190.9M.
Context
- EBITDA amounted to 4226.2% of revenue in FY2025, down 2135.0 pp from a year earlier.
- EBITDA grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 8 analysts of -$134.71M (+31.2%) for the fiscal year ending Dec 2026, a step up from the -3.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$47.27M-6.9% QoQ
- Last fiscal yearDec 2025
- -$195.76M-3.2% YoY
- LTMMar 2026
- -$190.9M+2.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +5.8% | +13.3% | +7.5 pp |
| 1 year | -3.2% | +31.2% | +34.4 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (195.76M) USD
- Year-over-year change
- -3.2%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (195.76M) | -3.2% |
| FY2024 | 2024-12-31 | (189.75M) | -1.7% |
| FY2023 | 2023-12-31 | (186.64M) | -54.8% |
| FY2022 | 2022-12-31 | (120.55M) | +27.1% |
| FY2021 | 2021-12-31 | (165.29M) | — |
EBITDA vs competitors
How PRME compares with its peers on the latest reported figures
- PRME's LTM Mar 2026 EBITDA of -$190.9M is the 5th highest of the 7 companies compared; the peer median is -$106.03M.
- Its year-over-year change of +2.4% is the 5th highest of 7, against a peer median of +24.4%.
- EBITDA amounts to 4732.2% of revenue for PRME, versus a peer median of 581.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | -$63.18M | +83.2% | — | 40.5% | |
| LTM Mar 2026 | -$69.09M | -24.3% | — | — | |
| LTM Mar 2026 | -$100.08M | +56.8% | — | 258.7% | |
| LTM Mar 2026 | -$111.97M | +23.4% | — | 999.5% | |
| LTM Mar 2026 | -$190.9M | +2.4% | — | 4732.2% | |
| LTM Mar 2026 | -$384.61M | +25.4% | — | 581.9% | |
| LTM Sep 2026 | -$482.67M | -3.6% | — | 1917.5% | |
SCTXScribe Therapeutics Inc. | — | — | — | — | — |
| Peer median (excluding PRME) | -$106.03M | +24.4% | — | 581.9% | |
Competitors are the stored peer set for PRME. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 2.98M | 4.63M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 7.32M |
| Gross Profit | 0 | 0 | 0 | 2.98M | (2.69M) |
| Gross Margin | — | — | — | 100.0% | -58.1% |
| Research & Development | 70.55M | 86.73M | 147.91M | 155.29M | 160.64M |
| Selling, General & Admin | 13.92M | 29.82M | 43.39M | 50.16M | 52.35M |
| Operating Expenses | 84.47M | 116.54M | 204.79M | 205.45M | 205.66M |
| Depreciation & Amortization | 568K | 2.22M | 4.65M | 6.13M | 5.38M |
| EBITDA | (165.29M) | (120.55M) | (186.64M) | (189.75M) | (195.76M) |
| EBITDA Margin | — | — | — | -6361.2% | -4226.2% |
| Operating Income | (84.47M) | (116.54M) | (204.79M) | (202.47M) | (208.35M) |
| Operating Margin | — | — | — | -6787.4% | -4498.1% |
| Interest Income | 0 | 0 | 0 | 3.52M | 4.15M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (81.38M) | (6.23M) | 6.38M | 6.59M | 7.21M |
| Income Before Tax | (165.85M) | (122.77M) | (198.41M) | (195.88M) | (201.14M) |
| Pre-Tax Margin | — | — | — | -6566.6% | -4342.4% |
| Income Tax Expense | (486K) | (948K) | (279K) | 0 | 0 |
| Net Income | (165.37M) | (121.82M) | (198.13M) | (195.88M) | (201.14M) |
| Net Margin | — | — | — | -6566.6% | -4342.4% |
| EPS (Basic) | (1.92) | (1.46) | (2.18) | (1.65) | (1.35) |
| EPS (Diluted) | (1.92) | (1.46) | (2.18) | (1.65) | (1.35) |
| Weighted Avg Shares | 95.73M | 97.21M | 90.97M | 118.6M | 148.76M |
| Weighted Avg Shares (Diluted) | 95.73M | 97.21M | 90.97M | 118.6M | 148.76M |
Prime Medicine, Inc.
NASDAQ:PRME
Intrinsic Alpha fair value
Locked
Current Price
$3.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.